I-Mab and Nhwa Announce Novel Alzheimer's Drug Starts US Trials
December 08, 2021 at 05:13 AM EST
Shanghai I-Mab announced that the first patient has been dosed in a US Phase I study of Protollin, a novel immune therapy for Alzheimer's disease. Protollin is composed of outer membrane proteins of bacteria complexed with lipopolysaccharides. In preclinical tests, it modulated immune cells and showed potential to treat disorders that have an immune component. It is delivered via a nasal spray to reach the brain. I-Mab and Nhwa Pharma, a Jiangsu CNS company. share global rights to Protollin. More details.... Stock Symbols: (NSDQ: IMAB) (SHZ: 002262) Share this with colleagues: // //